TY - JOUR
T1 - Establishment and Utility of SwedAD
T2 - A Nationwide Swedish Registry for Patients with Atopic Dermatitis Receiving Systemic Pharmacotherapy
AU - Alsterholm, Mikael
AU - Svedbom, Axel
AU - Anderson, Chris D
AU - Holm Sommar, Lena
AU - Ivert, Lina U
AU - Josefson, Anna
AU - Von Kobyletzki, Laura
AU - Lindberg, Magnus
AU - Lundeberg, Lena
AU - Lundqvist, Maria
AU - Nylander, Elisabet
AU - Sandström Falk, MariHelen
AU - Shayesteh, Alexander
AU - Sigurdardottir, Gunnthorunn
AU - Sonesson, Andreas
AU - Svensson, Åke
AU - Virtanen, Marie
AU - Vrang, Sophie
AU - Wahlgren, Carl-Fredrik
AU - Bradley, Maria
AU - Johansson, Emma K
PY - 2023/4/6
Y1 - 2023/4/6
N2 - SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis.
AB - SwedAD, a Swedish nationwide registry for patients with atopic dermatitis receiving systemic pharmacotherapy, was launched on 1 September 2019. We describe here the establishment of a user-friendly registry to the benefit of patients with atopic dermatitis. By 5 November 2022, 38 clinics had recorded 931 treatment episodes in 850 patients with an approximate national coverage rate of 40%. Characteristics at enrolment included median Eczema Area and Severity Index (EASI) 10.2 (interquartile range 4.0, 19.4), Patient-Oriented Eczema Measure (POEM) 18.0 (10.0, 24.0), Dermatology Life Quality Index (DLQI) 11.0 (5.0, 19.0) and Peak Itch Numerical Rating Scale-11 (NRS-11) 6.0 (3.0, 8.0). At 3 months, median EASI was 3.2 (1.0, 7.3) and POEM, DLQI, and NRS-11 were improved. Regional coverage varied, reflecting the distribution of dermatologists, the ratio of public to private healthcare, and difficulties in recruiting certain clinics. This study highlights the importance of a nationwide registry when managing systemic pharmacotherapy of atopic dermatitis.
KW - Humans
KW - Dermatitis, Atopic/drug therapy
KW - Sweden
KW - Severity of Illness Index
KW - Registries
KW - Eczema
KW - Quality of Life
U2 - 10.2340/actadv.v103.7312
DO - 10.2340/actadv.v103.7312
M3 - Article
C2 - 37021597
SN - 1651-2057
VL - 103
SP - 1
EP - 7
JO - Acta Dermato-Venereologica
JF - Acta Dermato-Venereologica
M1 - adv7312
ER -